Complete Genomics, a California biotechnology company aiding in genetic cancer detection, faces potential exclusion from the U.S. market due to ties to China, amid Congress’ efforts to counter Beijing’s global influence. The bipartisan push with the BIOSECURE Act aims to protect health data, reduce reliance on China in the medical supply chain, and advance U.S. biotech competitiveness. Opponents argue the bill would impede drug development and innovation. The legislation targets companies like Complete Genomics, BGI, MGI, WuXi AppTec, and WuXi Biologics, sparking debates about protecting Americans’ data and maintaining industry competition. For instance, Eli Lilly is shifting some manufacturing operations closer to home but warns of years-long challenges due to regulatory complexities.
Source link
Congress targets Chinese influence in health tech. It could come with tradeoffs
